AI Integration for Clinical Trial Medical Imaging Workflows

AI integration for clinical trial imaging focuses on three primary connection points: the PACS/VNA (e.g., Sectra, Intelerad) for study retrieval and preliminary analysis, the EDC (e.g., Medidata Rave, Oracle Clinical) for structured data and query workflows, and the centralized adjudication platform for case assembly and committee review. The core technical pattern involves using PACS DICOMweb or REST APIs to pull anonymized imaging series, running them through validated AI models for triage, quantification, or anomaly detection, and then pushing structured findings—such as lesion measurements, RECIST scores, or priority flags—into the EDC via its clinical data API (e.g., Rave Web Services) or a dedicated imaging CRF. This creates a machine-assisted read that pre-populates adjudication packets.

High-value use cases include automated RECIST 1.1 measurements for oncology trials, edema or hemorrhage volumetry for stroke studies, and anomaly triage for cardiac safety imaging. For example, an AI agent can monitor the PACS for new cardiac MRI studies in a cardio-oncology trial, calculate left ventricular ejection fraction (LVEF), and automatically flag studies with a significant drop from baseline for urgent cardiologist review within the EDC's query module. This shifts review from a batch-and-queue process to a real-time, event-driven workflow, reducing the time from scan to actionable data from weeks to hours.

A production implementation is typically wired through a secure, HIPAA/GCP-compliant middleware layer that handles DICOM de-identification, job queuing, model inference, and audit logging. Governance is critical: all AI outputs should be tagged as "machine-derived" within the EDC, require radiologist confirmation before locking, and be fully traceable back to the source image and model version. Rollout follows a phased approach, starting with a single imaging modality and trial phase to validate the data pipeline and user acceptance before scaling across the imaging core lab's workflow.

The core integration pattern involves a secure, event-driven pipeline. When a new imaging study is finalized in the PACS (e.g., Sectra, Intelerad) or VNA, a DICOM Study-Completed event or HL7 ORU message triggers an extraction service. This service anonymizes the study per protocol (removing PHI via gdcmanon or similar), pushes pixel data and metadata to a secure, transient storage layer, and posts a job to a processing queue. The AI agent—hosted within the trial's VPC—pulls the job, executes the model (e.g., for lesion quantification, RECIST measurement, or anomaly triage), and generates a structured JSON summary. This output is then posted via EDC REST APIs (Medidata Rave, Oracle Clinical) to pre-defined forms or via a clinical data warehouse API for aggregation, linking the AI read to the patient's clinical record and visit data.

Critical guardrails are implemented at each layer. Data never leaves the sponsor's or CRO's controlled cloud environment; all processing occurs within the trial's dedicated, compliant infrastructure (e.g., AWS HealthLake Imaging, Azure DICOM Services). A human-in-the-loop review interface is mandatory, often built into existing imaging review platforms or as a lightweight web app. Here, radiologists or central reviewers can accept, modify, or reject AI-generated findings, with every action logged to an immutable audit trail. The system enforces role-based access control (RBAC) synced with the CTMS (Veeva Vault CTMS, Oracle Clinical One) to ensure only authorized adjudicators can view or alter results. Finally, all prompts, model versions, input data hashes, and outputs are versioned and traced in an LLMOps platform (Weights & Biases, Arize AI) for reproducibility and regulatory inspection.

Rollout follows a phased, protocol-specific validation. Start with a single imaging modality (e.g., CT) and a non-critical endpoint in a pilot site. Use the AI output as a "second reader" to benchmark against manual reads, measuring concordance rates and time-to-adjudication. Integrate feedback loops where reviewer corrections are used to fine-tune prompts or retrain models (in a closed loop). Only after validation and SOP updates should the AI be used for primary endpoint support. This architecture, emphasizing secure data flow, immutable audit, and human oversight, turns AI from a black-box tool into a governed, scalable component of the clinical imaging workflow, aiming to shift endpoint adjudication from weeks to days while maintaining GCP compliance.

A production AI integration for medical imaging must be built on a governed data pipeline. This typically involves a secure service that listens for new imaging studies from the PACS system (e.g., via DICOMweb or HL7), extracts anonymized or de-identified data for processing, and routes the AI output—such as a triage score, anomaly flag, or draft summary—to a review queue within the Clinical Data Management System (CDMS) or EDC. Critical design points include maintaining a full audit trail linking the original image, the AI model version and prompt used, the generated output, and the final adjudicator's decision. Access must be role-based, ensuring only authorized medical monitors or central reviewers can see AI-suggested findings before they are officially entered into the trial database.

Rollout follows a phased, validation-centric approach. Phase 1 is a silent pilot: AI processes images in parallel with the standard workflow, but its outputs are logged and compared to human reads without impacting the trial. This builds a performance baseline and refines prompts. Phase 2 introduces AI as an assistant: flagged studies or draft summaries are presented to reviewers within their EDC or clinical workbench as "AI Suggestions," requiring explicit acceptance or modification. This phase often focuses on low-risk tasks like triaging normal scans for rapid clearance or drafting routine findings. Phase 3, full integration, automates the population of specific eCRF fields or triggers workflow alerts only for high-confidence, pre-validated use cases, always with a clear path for human override and documented rationale.

Compliance is engineered into the workflow. The system must support 21 CFR Part 11 requirements for electronic signatures and audit controls. AI model changes are treated as a configuration change under the trial's change control procedures. Furthermore, the integration design should facilitate ALCOA+ principles for data integrity: Attributable (who approved the AI output?), Legible, Contemporaneous, Original, and Accurate. By treating the AI agent as a governed component within the existing validated system landscape—not a black-box replacement—sponsors can accelerate endpoint adjudication while maintaining the rigorous control demanded by regulators and protocol.